is exciting from a biological perspective, full delivery of the promise of genetically driven medicine will require that we make the leap from knowledge of cancer genetic events and translate this information into new and personalized therapeutic regimens for patients.
T erapies that are targeted to cancercausing genetic abnormalities have improved patient outcomes for cancers with well-def ned genetic drivers. Extrapolation of this paradigm of targeted therapy to all malignancies will require the subdivision of cancer into distinct entities with operationally important mutant genes, knowledge of the signaling pathways that become dysregulated as a consequence of these mutant genes, and the ability to match the dysregulated pathways with cocktails of ef ective, targeted therapeutic agents. T is task of matching genetic information from deep sequencing with clinically meaningful therapies will require the integration of genomic data with functional information regarding drug sensitivity patterns of cancer cells. Integration of data in this manner has been the primary emphasis of my research program (Fig. 1) , and this article will highlight some of the f ndings that have been made with such an integrated approach.
FUNCTIONAL GENOMICS FOR PERSONALIZED MEDICINE
With the goal of quickly identifying actionable gene targets in individual hematologic malignancy patients, I sought to develop a
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Functional Genomics for Personalized Cancer Therapy
Jef rey W. Tyner Fig. 1 . Functional genomics approach: current and future. To comprehensively defi ne the functional genomic landscape of cancer, we are currently performing parallel analyses of primary specimens from patients with hematologic malignancies. Genomic analysis reveals a large number of genetic events, most of which are seen in very small fractions of patients. Functional screening shows heterogeneous patterns of drug sensitivity with unclear genetic etiology. By integrating these data streams, we have identifi ed pathogenetically important and clinically actionable genetic events, such as dependence on ROR1 and the pre-B cell receptor in t(1;19)-ALL and mutant CSF3R signaling in CNL. As we learn more from this platform, we build toward a future in which personalized, targeted therapies are prescribed solely on the basis of rapid genomic analysis of individual patient tumor specimens. 
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RNA interference (RNAi)-based screen that could be applied directly to primary cells from patients. One of the early specimens I analyzed in this manner showed a dramatic sensitivity to silencing of the nonreceptor tyrosine kinase JAK2. Sequence analysis of JAK2 and other genes that can regulate JAK2 revealed an abnormal two-base-pair insertion in the thrombopoietin receptor MPL, which signals upstream of JAK2. I conf rmed the transformative capacity of this mutant gene as well as its capacity to dysregulate JAK2 signaling. T e patient from whom this specimen was drawn was treated on a clinical trial with a kinase inhibitor, midostaurin, that exhibits potent activity against JAK2, and the patient exhibited a dramatic response to this therapeutic agent (1) . A further search for patient specimens harboring this two-base-pair insertion in MPL revealed no other patients out of thousands screened, suggesting that functional testing can identify important gene targets irrespective of their disease frequency but that ef ective use of this technology to unveil all relevant gene targets will require screening of much larger cohorts of patients. As such, I developed a high-throughput platform with which my research team has collectively analyzed nearly 1000 cases with RNAi and/or a parallel smallmolecule inhibitor screening approach (2). We have additionally analyzed many of these same specimens with deep-sequencing technology. T is platform has led to the discovery of numerous actionable genetic lesions, with two of the most notable described here.
T(1;19)-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
Functional screening of specimens from patients with acute lymphoblastic leukemia (ALL) harboring a 1;19 chromosomal translocation showed consistent sensitivity to silencing of the cell surface receptor ROR1 and to the U.S. Food and Drug Administration-approved kinase inhibitor dasatinib. Genomic analysis revealed that ROR1 expression is elevated in all t(1;19)-ALL cases compared with other ALL subsets. Follow-up validation work revealed that dasatinib sensitivity in this setting is mediated through dependence of t(1;19)-ALL cells on signaling from the pre-B cell receptor, which signals through SRC family kinases that are potent targets of dasatinib. We also discovered that ROR1 and the pre-BCR signal cooperatively to promote the viability and growth of t(1;19)-positive ALL cells. Collectively, these f ndings revealed new therapeutic targets and regimens that can be used for t(1;19)-ALL patients, who comprise ~5% of pediatric ALL cases and ~1 to 2% of adult ALL cases (3) .
In addition to t(1;19)-ALL cases, we also showed that a related subset, t(17;19)-ALL, exhibits high levels of ROR1 as well as sensitivity to pre-BCR antagonists such as dasatinib. T e 17;19-translocation is extremely rare and carries a dismal prognosis with no reported cases of survivorship. One patient with t(17;19)-ALL has been treated with dasatinib with clinical benef t (4), but this patient's clinical response was transient, highlighting the need for combination therapy approaches. T ese approaches are also being advanced in the setting of chronic lymphocytic leukemia, in which similar observations of elevated ROR1 expression and dependence on B cell receptor signaling have been made, and major ef orts are under way to use antibodies and chimeric antigen T cell receptors that can target ROR1 (5, 6) . All together, these strategies of simultaneous antagonism of ROR1 and the B cell receptor are poised to greatly improve clinical treatment options for patients with t(1;19)-ALL, t(17;19)-ALL, and mature B cell neoplasms.
PHILADELPHIA-NEGATIVE CHRONIC MYELOID LEUKEMIA
Chronic neutrophilic leukemia (CNL) and atypical (BCR-ABL1-negative) chronic myeloid leukemia (aCML) are both hematologic malignancies that have historically been diagnosed on the basis of neoplastic expansion of granulocytic cells and exclusion of genetic drivers known to occur in other myeloproliferative neoplasms. T e primary genetic basis of both CNL and aCML has remained unknown, and this absence of def ning genetic lesions has made diagnosis of these diseases challenging, resulting in a dearth of ef ective therapeutic options for patients. To identify driver kinase oncogenes in CNL/aCML, we applied our functional genomics approach to interrogate primary cells from a cohort of patients with CNL/ aCML. In this disease setting, our functional genomics approach led to the identif cation of gain-of-function CSF3R mutations in ~60% of CNL and aCML patients (7) .
CSF3R is the receptor for colonystimulating factor 3 (CSF3; GCSF) and is known to play a prominent role in the growth and dif erentiation of granulocytes. CSF3R mutations have been described in patients with severe congenital neutropenia, which can evolve into acute myeloid leukemia (8), but they had not previously been described in de novo leukemia. CSF3R has been shown to signal through both the Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway and SRC family kinases. CSF3R mutations cluster into two distinct regions of the receptor, with the majority of mutations falling in the extracellular domain (membrane-proximal mutations) and the remainder being nonsense/missense mutations that truncate the cytoplasmic tail (truncation mutations). Our parallel functional analysis of specimens harboring these two distinct mutation types revealed dif erential mechanisms of activation, resulting in divergent downstream signaling and sensitivity to small-molecule inhibitors. We found that membrane-proximal mutations conferred ligand independence, which resulted in sensitivity to inhibitors of JAK kinases. We further showed that the ligand independence observed in the setting of these membrane-proximal mutations is due to constitutive receptor dimerization and that the mutated residues are sites of Olinked glycosylation, which is abrogated in the context of these mutations (9) . In contrast, truncation mutations conferred receptor overexpression and ligand hypersensitivity, resulting in sensitivity to inhibitors of SRC family kinases as well as a new CSF3R signaling mediator, TNK2.
Multiple CSF3R-mutant CNL patients have now been treated with single-agent kinase inhibitors, resulting in dramatic and durable clinical responses, although CSF3R mutations can occur in the context of additional genetic events such as SETBP1 (10) , suggesting an ultimate need for combination therapies. Cumulatively, these f ndings have def ned a new subtype of hematologic malignancy and have enabled an ef cient genetic test that can be used to identify patients who can now be treated with targeted therapeutic regimens.
Taken together, functional genomic screening has already enabled the def nition of multiple new subtypes of cancer, and these subtypes can be matched with immediately available targeted therapies. Continuation of this strategy holds tremendous promise for the further ref nement of our understanding of specif c cancer subsets based on genetic events, and matching these f ne-tuned patient subsets with drug sensitivity patterns marks a major step toward optimal use of comprehensive genomic information for cancer therapy.
